Act Capital Management
Act Capital Management reported 62 stocks worth $153M in its 13F filing for Q2 2026, filed Jul 29, 2026. Its largest holdings are KRYS (10.9%), TGTX (9.0%) and ABVX (8.4%). Compared with Q1 2026, the fund opened new positions in TSLA, ASTS and PVLA, added to TGTX, ABVX and XOM, trimmed KRYS, CELC and CYTK and sold out of STAA, S and LITE.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  KRYS Krystal Biotech Inc | $16.7M | 10.9% | 45K | −15K (−26%) | 3 of 3 | |
| 2 |  TGTX TG Therapeutics Inc | $13.8M | 9.0% | 251K | +2,000 (+1%) | 3 of 3 | |
| 3 |  ABVX Abivax SA | $12.9M | 8.4% | 97K | +26K (+37%) | 3 of 3 | |
| 4 |  CVX Chevron Corp New | $12.4M | 8.1% | 75K | No change | 3 of 3 | |
| 5 |  XOM Exxon Mobil Corp | $10.7M | 7.0% | 79K | +8,500 (+12%) | 3 of 3 | |
| 6 |  ARWR Arrowhead Pharmaceuticals in | $9M | 5.9% | 110K | +28K (+33%) | 3 of 3 | |
| 7 |  VKTX Viking Therapeutics Inc | $8.2M | 5.3% | 209K | No change | 3 of 3 | |
| 8 |  CELC Celcuity Inc | $6.5M | 4.3% | 62K | −30K (−32%) | 3 of 3 | |
| 9 |  NKTR Nektar Therapeutics | $6.2M | 4.1% | 89K | +18K (+26%) | 3 of 3 | |
| 10 |  TSLA Tesla Inc | $4.5M | 3.0% | 11K | New position | 1 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 STAA Staar Surgical Co | $1M | 56K |
 S Sentinelone Inc | $699K | 54K |
 LITE Lumentum Hldgs Inc | $632K | 900 |
 CRCL Circle Internet Group Inc | $572K | 6,000 |
 NVDA Nvidia Corporation | $488K | 2,800 |
🔒 Free account: see all 14.
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Jul 29, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Act Capital Management 13F FAQ
What does Act Capital Management own?
Act Capital Management reported 62 stocks worth $153M in its 13F filing for Q2 2026, filed Jul 29, 2026. Its largest holdings are KRYS (10.9%), TGTX (9.0%) and ABVX (8.4%). The table above lists every position in the filing (the top 10 without an account).
What did Act Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 20 new positions, 15 added to, 12 trimmed and 14 sold out. New positions include TSLA, ASTS and PVLA. It sold all of STAA, S and LITE.
When will Act Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Act Capital Management's portfolio worth?
The Q2 2026 filing reports $153M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.